BioNTech SE is a global next-generation immunotherapy company focused on developing novel medicines for cancer, infectious diseases, and other serious conditions. The company leverages the immune system's power to address diseases with unmet medical needs and significant global health burdens. BioNTech primarily sells mRNA vaccines, protein-based therapeutics, cell therapies, and small molecules.
- COVID-19 Vaccine Revenues - Generates revenue from the sale of COVID-19 vaccines, which is the major contributor to the company's revenue.
- Share of Collaboration Partners' Gross Profit - Receives a share of the gross profit from collaboration partners, primarily Pfizer, based on sales in their territories.
- Direct Product Sales to Customers - Supplies the COVID-19 vaccine directly in territories like Germany and Türkiye.
- Sales to Collaboration Partners - Manufactures and sells products to collaboration partners.
- Research & Development Revenues from Collaborations - Earns revenue from R&D collaborations.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Prof. Ugur Sahin, M.D. ExecutiveBoard | CEO and Co-Founder | None | CEO and Co-Founder of BioNTech, actively involved in strategic and operational development, particularly in oncology and COVID-19 vaccine efforts. | View Report → |
Jens Holstein Executive | Chief Financial Officer (CFO) | Non-executive board member at Veracyte Inc. | Joined BioNTech in 2021; previously CFO at MorphoSys AG and held multiple CFO/general management roles at Fresenius SE Group. | |
Ryan Richardson Executive | Chief Strategy Officer (CSO) | None | Joined BioNTech in 2018; previously worked in healthcare investment banking at J.P. Morgan and as a health economist at IMS Health. | |
Sean Marett Executive | Chief Business Officer (CBO) and Chief Commercial Officer (CCO) | Chairman of PHMR Ltd; Supervisory board member at AiCuris AG | Joined BioNTech in 2012; led commercialization of the Pfizer-BioNTech COVID-19 vaccine and negotiated key financing rounds and supply agreements. | |
Sierk Poetting, Ph.D. Executive | Chief Operating Officer (COO) | None | Joined BioNTech in 2014; previously held leadership roles at Novartis and worked as a consultant at McKinsey & Company. | |
Baroness Nicola Blackwood Board | Supervisory Board Member | Chair of Oxford University Innovation; Chair of Genomics England; Managing Director of Blackwood Intelligence Limited; Member of the House of Lords | Appointed to the Supervisory Board in 2023; brings expertise in science and innovation; holds leadership roles in prominent UK organizations. | |
Helmut Jeggle Board | Chair of the Supervisory Board | Managing Partner at Salvia GmbH; Supervisory board member at 4SC AG, Tonies SE, AiCuris AG, AFFiRiS AG, APK AG | Chair of BioNTech's Supervisory Board since 2008; instrumental in guiding the company’s strategic direction; previously held roles at Hexal AG and ATHOS KG. | |
Michael Motschmann Board | Supervisory Board Member | Co-founder and Management Board member at MIG Capital AG; Supervisory board member at APK AG, HMW Emissionshaus AG, Affiris AG; Advisory board member at Efficient Energy GmbH, Temedica GmbH, AMSilk GmbH | Supervisory Board member since 2008; co-founder of MIG Capital AG and active in venture capital investments. |
-
Although you have significant ongoing Phase II and III trials, could you elaborate on how you plan to balance the increasing R&D expenses with cost control measures, especially as you invest in assets like BNT327?
-
With regards to your updated guidance at the low end of the range due to low demand and pricing in low and middle income countries, how do you plan to mitigate these challenges and ensure revenue growth in the face of reduced COVID-19 vaccine demand?
-
Given the approximately EUR 600 million accrued for contractual disputes with licensees and collaborators this year, can you provide more clarity on the nature of these disputes and how they might impact future financials?
-
Considering the missed endpoints in the Phase III flu COVID combo program and competitors like Moderna expecting to launch their combo next year, how are you adjusting your strategy to remain competitive in the combination vaccine market?
-
As you expect to maintain or gain market share in key markets this year for your COVID-19 vaccine and believe in improved visibility into vaccine demand, how confident are you in your ability to sustain this given potential shifts in vaccination rates and market dynamics?
Research analysts who have asked questions during BioNTech earnings calls.
Cory Kasimov
Evercore ISI
4 questions for BNTX
Daina Graybosch
Leerink Partners
4 questions for BNTX
Jessica Fye
JPMorgan Chase & Co.
4 questions for BNTX
Tazeen Ahmad
Bank of America
4 questions for BNTX
Terence Flynn
Morgan Stanley
4 questions for BNTX
Yaron Werber
TD Cowen
4 questions for BNTX
Akash Tewari
Jefferies
3 questions for BNTX
Asthika Goonewardene
Truist Securities
2 questions for BNTX
Harry Gillis
Berenberg
2 questions for BNTX
Mohit Bansal
Wells Fargo & Company
2 questions for BNTX
Asad Haider
Goldman Sachs
1 question for BNTX
Chris Shibutani
Goldman Sachs Group, Inc.
1 question for BNTX
Eliana Merle
UBS
1 question for BNTX
Evan Seigerman
BMO Capital Markets
1 question for BNTX
Jay Olson
Oppenheimer & Co. Inc.
1 question for BNTX
John Newman
Canaccord Genuity Group Inc.
1 question for BNTX
Manos Mastorakis
Deutsche Bank
1 question for BNTX
Nishan Sarna
Citigroup
1 question for BNTX
Simon Baker
Redburn Atlantic
1 question for BNTX
Suzanne van Voorthuizen
Kempen & Co
1 question for BNTX
Yifeng Liu
HSBC
1 question for BNTX
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Biotheus | 2025 | BioNTech’s acquisition of Biotheus was aimed at strengthening its oncology portfolio with the BNT327 pan-tumor platform; the deal’s total value was $800 million in cash (plus a small portion in ADS) with up to $150 million in performance-based payments, providing full global rights to BNT327, access to an in-house antibody generation platform, and a new R&D hub and manufacturing facility as an indirect Chinese subsidiary. |
InstaDeep | 2023 | BioNTech’s acquisition of InstaDeep involved buying 100% of the remaining shares for approximately €500 million, structured with cash, BioNTech shares, and milestone-based payments, to integrate AI/ML capabilities across industries while InstaDeep continues as a UK-based global subsidiary. |
Medigene | 2022 | In 2022, BioNTech collaborated with and acquired key assets from Medigene, including its next-generation preclinical TCR program (PRAME TCR) and licenses to the PD1-41BB switch receptor, for an upfront payment of EUR 26 million plus milestone, regulatory, and commercial payments, thereby securing exclusive worldwide rights to further TCR immunotherapies. |
Recent press releases and 8-K filings for BNTX.
- BioNTech SE and Pfizer Inc. announced on August 27, 2025, that the U.S. Food and Drug Administration (FDA) has approved their LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1).
- The vaccine is approved for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
- Shipping of the LP.8.1-adapted vaccine will begin immediately, with availability in U.S. pharmacies, hospitals, and clinics in the coming days.
- The global mRNA Platform market is projected to decline from an estimated US$152.0 Billion in 2024 to US$129.1 Billion by 2030, representing a CAGR of -2.7%.
- This overall market trend is influenced by a projected decline in the COVID-19 Vaccine segment, which is expected to reach US$102.1 Billion by 2030 with a -6.3% CAGR.
- Conversely, the Cancer Vaccine segment is anticipated to grow significantly at an 86.1% CAGR over the analysis period.
- The U.S. market holds a leading position, valued at $64.5 Billion in 2024, with China forecasted to reach $13.8 Billion by 2030.
- Key drivers for the mRNA platform include increasing infectious diseases, technological advancements, and substantial investments in biotechnology research, supported by regulatory processes.
- The global vaccines market is projected to grow from $76.05 billion in 2024 to $118.85 billion by 2030, representing a Compound Annual Growth Rate of 7.72%.
- Technological innovations, such as messenger RNA platforms and synthetic biology, are revolutionizing vaccine development, allowing for rapid cycle designs and flexible formulations.
- U.S. tariff changes in 2025 are increasing raw material costs, necessitating new supply chain strategies and pushing manufacturers towards regional production hubs.
- Regional dynamics vary, with the Americas leveraging robust infrastructures, Europe and Africa facing mixed distribution capacities, and Asia-Pacific emerging as a manufacturing hub.
- BioNTech will acquire all shares of CureVac in an all-stock transaction valued at $1.25 billion, offering $5.46 in BioNTech ADS per CureVac share (a 55% premium to CureVac’s three-month VWAP) .
- Upon closing, CureVac shareholders are expected to own 4–6% of BioNTech, subject to regulatory approvals and an 80% minimum acceptance threshold (reducible to 75%) with support from shareholders representing 50.08% of CureVac shares .
- The acquisition aims to combine complementary capabilities in mRNA design, delivery, and production to strengthen cancer immunotherapy and therapeutic research efforts .
- CureVac shares surged 26%–30% in pre-market trading on the announcement, reflecting strong market optimism .
- BioNTech reported a Q1 2025 net loss of €416 million (up from €350 million in Q1 2024) with R&D expenses rising to €526 million, while analysts assign an “Outperform” rating with an average target price of $135.12 (implying ~28% upside) .
- BioNTech SE and Bristol Myers Squibb have entered a global strategic partnership to co-develop and co-commercialize the investigational bispecific antibody BNT327, which targets PD-L1 and VEGF-A to treat multiple solid tumor types.
- The agreement features a 50/50 profit/loss split and is set to accelerate clinical development through extensive trials, including registrational studies in several cancer indications.
- Investment Announcement: BioNTech SE’s subsidiary, BioNTech UK Ltd., signed a grant agreement with the UK Government to expand its R&D activities in the UK.
- Financial Commitment: The company committed to invest up to £1 billion over the next 10 years, while the UK Government will provide a grant of up to £129 million over the same period.
- Strategic Expansion: The funds will support the establishment of two new R&D centers (including one in Cambridge), the setup of a UK headquarters in London with an integrated AI hub, and the acceleration of clinical trials.
- Strategic expansion: Acquired Biotheus to secure full global rights for the antibody candidate BNT327, accelerating oncology development .
- Oncology pipeline advancement: Over 20 product candidates in Phase II/III studies, including mRNA cancer immunotherapies (FixVac and iNeST) and bispecific antibodies , .
- COVID-19 vaccine success: Delivered over 4.9 billion doses; planning variant-adapted vaccines for the 2025-2026 season .
- Robust financial foundation: Maintained a strong balance sheet with approximately EUR 2.8 billion in 2024 despite shifting COVID-19 demand .
- Operational & Financial Outlook: Q1 2025 performance review and 2025 outlook under the leadership of CEO Prof. Dr. Ugur Sahin, highlighting progress through fiscal 2024 and Q1 2025 .
- BioNTech reported Q1 2025 revenues of EUR 183 million [0,4] with a net loss of EUR 460 million (loss per share €1.73 ).
- Maintained robust liquidity with €15.9 bn in cash, cash equivalents & security investments [0,6,7].
- Provided full-year revenue guidance of EUR 1.7–2.2 billion .
- Advancing the oncology portfolio with BNT327 in Phase II/III trials for SCLC, TNBC and promising Phase 2 data in NSCLC [1,2,6,8].
- Strengthening its COVID-19 strategy with preparations for a variant-adapted vaccine [0,3] and sustaining >50% global market share for COMIRNATY .
- Corporate updates include the acquisition of Biotheus and the appointment of Ramón Zapata-Gomez as CFO effective July 1, 2025 [1,6,7,8].
- BioNTech SE will present clinical and preclinical data from its oncology pipeline, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, at the AACR Annual Meeting in Chicago from April 25-30, 2025.
- The presentations include first clinical data for the combination of the PD-L1xVEGF-A bispecific antibody candidate BNT327 with ADCs and results from a Phase 1 trial of the mRNA cancer immunotherapy candidate BNT116 in advanced NSCLC patients.
- Balance Sheet Profit Resolution: The management proposes carrying forward the full EUR 8,232,460,140.27 balance sheet profit from FY 2024.
- Board and Auditor Approvals: Resolutions include approving the actions of the Management and Supervisory Boards for FY 2024 and appointing EY as auditor for FY 2025, covering interim and sustainability reporting.
- Capital Increase Authorization: The company plans to cancel the existing Authorized Capital 2021 and establish new Authorized Capital 2025 amounting to EUR 124,276,100, with provisions to exclude subscription rights under certain conditions.